Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACIST: Amrubicin plus cisplatin with concurrent accelerated hyperfractionated thoracic radiotherapy in limited-disease small cell lung cancer
jRCT1071200033Phase 1Completed
- Start
- Oct 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amrubicin and cisplatin in small cell lung cancer (SCLC). Primary endpoint: Recommended dose. Started Oct 2020; status: completed.
02
Drugs
amrubicincisplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT1071200033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071200033.